Zolmitriptan Od Tablet, Orally Disintegrating
Product Images NDC 42291-998

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Zolmitriptan Od (NDC 42291-998). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

1 (998 06)

1 (998 06)
This is a description for Zolmitriptan Orally Disintegrating Tablets, USP containing 25 mg of Zolmitriptan per tablet. The text provides information on dosage and usage instructions. It is recommended to store the medication at 20°C-25°C and protect it from light and moisture. Please refer to the prescribing information for more details.*
FDA Label Image

1 (999 03)

1 (999 03)
This is a description about Zolmitriptan Orally Disintegrating Tablets, USP containing 5 mg of the active ingredient. The text also includes handling instructions such as protecting from light and moisture and storing at controlled room temperature. The product is numbered with the NDC code 42291.990.03.*
FDA Label Image

Zolmitriptan Structure (Structure)

Zolmitriptan Structure (Structure)
FDA Label Image

Fig 1 (Figure 1)

Fig 1 (Figure 1)
FDA Label Image

Fig 2 (Figure 2)

Fig 2 (Figure 2)
This text appears to be a chart showing estimated probabilities of remedication over time from the initial dose. The probabilities are represented as percentages. The data may be used for evaluating the likelihood of needing additional doses of medication at different time points.*
FDA Label Image

Fig 3 (Figure 3)

Fig 3 (Figure 3)
This text provides information on the percentage distribution of Zolmitriptan Orally Disintegrating Tablets (2.5 mg) and Placebo over time intervals from 0.5 hour to 2 hours after the initial dose.*
FDA Label Image

Fig 4 (Figure 4)

Fig 4 (Figure 4)
This text appears to be a chart or table related to Zolmitriptan Orally Disintegrating Tablets, specifically focusing on the estimated probability of remedication or rescue over a period of 24 hours after the initial dose. It likely provides information on the dosage strength of 2.5 mg and how it correlates with the likelihood of needing additional medication within specific time intervals.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.